SEC Form 4 · accession 0001209191-16-119690
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
John N Kapoor
Officer — President & CEO · Director · 10% Owner
Period of report
May 11, 2016
Accepted (ET)
May 12, 2016 · 7:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 11, 2016 | P | 40,000 | $12.9427 | A | 42,414,610 | I | By Trust |
| Common StockF3,F2 | May 12, 2016 | P | 10,000 | $12.4119 | A | 42,424,610 | I | By Trust |
| Common Stock | holding | — | — | — | 31,982 | D | ||
| Common StockF4 | holding | — | — | — | 56,288 | I | By Partnership |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.68 to $13.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- F2By The John N. Kapoor Trust dated September 20, 1989.
- F3The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.32 to $12.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- F4By EJ Financial/NEO Management, L.P. of which the reporting person is Managing General Partner.